CN116570707A - Application of galectin 1 in medicines for preventing and treating sepsis - Google Patents
Application of galectin 1 in medicines for preventing and treating sepsis Download PDFInfo
- Publication number
- CN116570707A CN116570707A CN202310757650.XA CN202310757650A CN116570707A CN 116570707 A CN116570707 A CN 116570707A CN 202310757650 A CN202310757650 A CN 202310757650A CN 116570707 A CN116570707 A CN 116570707A
- Authority
- CN
- China
- Prior art keywords
- galectin
- sepsis
- mice
- test
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 48
- 102000000795 Galectin 1 Human genes 0.000 title claims abstract description 30
- 108010001498 Galectin 1 Proteins 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 abstract description 10
- 230000004768 organ dysfunction Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000005986 heart dysfunction Effects 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000008816 organ damage Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 35
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000000683 abdominal cavity Anatomy 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 230000008828 contractile function Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004536 heart mitochondria Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an application of galectin 1 in medicines for preventing and treating sepsis. The galectin 1 has wide biological activity, can protect and regulate myocardial cells, can protect the sepsis heart dysfunction by taking the galectin 1 as a protein active drug, and can obviously regulate and control the immune system, inhibit excessive inflammatory reaction and reduce organ damage and dysfunction, thereby playing a role in preventing and treating sepsis.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of galectin 1 in medicines for preventing and treating sepsis.
Background
Sepsis is a highly heterogeneous syndrome caused by an unbalanced host response to infection. Sepsis is defined as a Systemic Inflammatory Response Syndrome (SIRS) caused by an infection, a life threatening organ dysfunction caused by a host's imbalance in the response to an infection. Notably, although infection is a triggering event in the definition of sepsis, an aberrant immune response is often still present after successful treatment of the infection. Sepsis places a significant burden on the world in terms of morbidity and mortality. Our understanding of the pathophysiology of sepsis has greatly progressed, while the development of targeted therapies for sepsis patients with disrupted host responses has failed, with a significant contrast. Disproportionate inflammatory response to invasive infection has been considered central to the onset of sepsis for many years, but it is now clear that host response is disturbed in a more complex manner, including sustained excessive inflammation and immunosuppression, and failure to restore normal homeostasis. It may be thought that during sepsis, there is not only an increase in inflammation and/or immunosuppression, but also a fundamental recombination of immune and metabolic cellular processes, measures of inflammation and suppression being a reflection of this acute cellular reprogramming. Furthermore, although animal studies and human observations have revealed pathological changes in many different components of the host response during sepsis, the key mechanisms of sepsis-related pathology are still difficult to form into an overall framework compared to secondary, less patient-prognosis-affecting disorders.
Clinical manifestations of sepsis vary widely depending on the initial site of infection, pathogenic microorganisms, the pattern of acute organ dysfunction, the underlying health of the patient, and the interval before initiation of treatment. Signs of infection and organ dysfunction may not be apparent, but acute organ dysfunction most often affects the respiratory and cardiovascular systems. Respiratory impairment is often manifested as Acute Respiratory Distress Syndrome (ARDS), defined as hypoxia with non-cardiac bilateral infiltration. Cardiovascular damage is primarily manifested by hypotension or elevated serum lactate levels. After sufficient expansion, hypotension often persists, requiring the use of vasopressors, and myocardial dysfunction may occur.
The mechanism of sepsis-related cardiac dysfunction appears to be multifactorial. In recent years, our understanding of the role of various mechanisms of circulatory heart inhibitors, calcium, NO, apoptosis, and mitochondrial dysfunction in the development of sepsis-associated myocardial dysfunction has been improved. Experiments and clinical studies have shown that ultrastructural abnormalities in cardiac mitochondria occur during sepsis. Furthermore, increased levels of NO and superoxide produced by cardiac mitochondria during sepsis may inhibit OXPHOS, reduce ATP production, and lead to "cytopathic hypoxia", i.e., impairment of cellular oxygen utilization and ATP production, which is a critical step in the development of sepsis-induced organ failure.
Early studies therefore emphasized strategies such as by improving endothelial and epithelial cell barrier function, bioenergy, and active inflammatory elimination pathways, or the adoption of cell therapy. However, since the molecular level cascade of sepsis systemic infections and organ dysfunction can occur simultaneously and often exhibit self-reinforcing characteristics, even if the heterogeneity of patients can be reduced and similar pathophysiological changes screened, it remains impractical to expect significant improvement in clinical prognosis by blocking one of the numerous pathways. At the same time, these treatment modalities are also limited by the limitations of preclinical models.
Disclosure of Invention
In order to solve the defects in the prior art, the invention aims to provide the application of the galectin 1 in medicines for preventing and treating sepsis.
The technical scheme for solving the technical problems is as follows:
use of galectin 1 in medicine for preventing and/or treating sepsis.
Further, the medicament is a preparation prepared from an active ingredient and an auxiliary ingredient, wherein the active ingredient comprises galectin 1 and a pharmaceutically acceptable galectin 1 derivative (comprising derivative polypeptide), and the auxiliary ingredient comprises pharmaceutically acceptable auxiliary materials.
Further, galectin 1 was purchased from the company of the division of the holy biotechnology (Shanghai) of next.
The dosage forms of the medicine comprise oral preparations or injection preparations.
The invention has the following beneficial effects:
1) The invention discovers that the galectin 1 (galectin-1) molecule can play a protective role in the function of the septic heart dysfunction as a protein active drug through a mouse test.
2) The invention discovers that the effect of the galectin 1 molecule is very prominent aiming at complex changes caused by sepsis through a mouse test. Whereas galectin 1 can significantly regulate the immune system, inhibit excessive inflammatory reaction, and reduce organ damage and dysfunction.
3) The invention adopts the intraperitoneal injection of LPS to simulate sepsis of mice, thereby observing the heart function and heart damage of the mice. The model utilizes the characteristic that LPS can trigger in-vivo acute inflammatory reaction, well simulates the characteristics of heart function decline, myocardial damage and the like under the condition of sepsis, and meanwhile, due to the metabolizability of LPS, mice cannot generate excessive heterogeneity due to individual difference and the like unlike systemic infection of sepsis. Thus in this model, inhibition of hyperimmune by galectin 1 can be directly observed, as well as protection of the heart in hyperimmune.
Drawings
FIG. 1 is a flow chart of a test protocol of the present invention;
FIG. 2 is the results of the ultrasonic testing of the heart of the mice of example 1;
FIG. 3 is a photograph of a stained section of the heart of a mouse of example 2;
fig. 4 is an electron micrograph of mitochondrial staining of myocardial tissue of the mice of example 3.
FIG. 5 is a graph showing the calcium transient and cell contraction assays of the mouse cardiomyocytes of example 4.
Detailed Description
The examples given below are only intended to illustrate the invention and are not intended to limit the scope thereof. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1: ultrasonic test of mouse heart
(1) Experimental animal
18 wild C57BL/6J mice are subjected to standardized maintenance feed feeding in a constant temperature environment for at least 1 week before the experiment, and drinking water is not limited.
(2) Grouping
Mice 18 were divided into 3 groups: control 6, test 6, sepsis 6.
Injecting physiological saline into the abdominal cavity 1h after the start of the test of the control group, wherein the injection amount is 5mg/kg based on the weight of the mice;
the test group test begins to inject the galectin 1 into the mice with the injection amount of 10 mug/mouse, and the lipopolysaccharide is injected into the abdominal cavity after 1h, wherein the injection amount is 5mg/kg based on the weight of the mice;
lipopolysaccharide was injected into the abdominal cavity 1h after the start of sepsis group test, the injection amount was 5mg/kg based on the weight of mice.
(3) Test method
After 19 hours from the start of the test, three groups of mice were subjected to cardiac ultrasound, and the heart functions of the mice were determined by analyzing the left ventricular contractile function (EF) and the left ventricular contractile rate (FS) of the hearts of the mice by cardiac ultrasound.
(4) Test results
As shown in fig. 2, it can be seen from the graph that the left ventricular contractile function (EF) and the left ventricular shortening rate (FS) were significantly reduced in the mice of the sepsis group compared to the control group, indicating that the heart function was significantly reduced in the mice of the sepsis group, whereas the left ventricular contractile function (EF) and the left ventricular shortening rate (FS) were significantly increased in the mice of the test group injected with galectin 1 compared to the sepsis group, indicating that the heart function reduction caused by sepsis can be effectively treated after galectin 1 is injected.
Example 2: mouse heart staining section test
(1) Experimental animal
18 wild C57BL/6J mice are subjected to standardized maintenance feed feeding in a constant temperature environment for at least 1 week before the experiment, and drinking water is not limited.
(2) Grouping
Mice 18 were divided into 3 groups: control 6, test 6, sepsis 6.
Injecting physiological saline into the abdominal cavity 1h after the start of the test of the control group, wherein the injection amount is 5mg/kg based on the weight of the mice;
the test group test begins to inject the galectin 1 into the mice with the injection amount of 10 mug/mouse, and the lipopolysaccharide is injected into the abdominal cavity after 1h, wherein the injection amount is 5mg/kg based on the weight of the mice;
lipopolysaccharide was injected into the abdominal cavity 1h after the start of sepsis group test, the injection amount was 5mg/kg based on the weight of mice.
(3) Test method
After 25h from the beginning of the test, i.e. 24h after injection of physiological saline or lipopolysaccharide, the hearts of three groups of mice were taken out, fixed with paraformaldehyde, then paraffin-embedded, sectioned, stained with Masson kit and observed.
(4) Test results
The test results are shown in fig. 3, and it can be seen from the graph that the heart muscle injury of mice in the sepsis group has obvious fibrosis symptoms relative to the control group, and the test group injected with the galectin 1 has less fibrosis and compact myocardial structure relative to the sepsis group, so that the symptoms of the heart muscle injury caused by the sepsis after the galectin 1 is injected are relieved, and myocardial tissues are protected.
Example 3: mouse heart mitochondrion staining electron microscope test
(1) Experimental animal
18 wild C57BL/6J mice are fed with standard maintenance feed in a constant temperature environment for at least 1 week before the experiment, and the drinking water is not limited.
(2) Grouping
Mice 18 were divided into 3 groups: control 6, test 6, sepsis 6.
Injecting physiological saline into the abdominal cavity 1h after the start of the test of the control group, wherein the injection amount is 5mg/kg based on the weight of the mice;
the test group test begins to inject the galectin 1 into the mice with the injection amount of 10 mug/mouse, and the lipopolysaccharide is injected into the abdominal cavity after 1h, wherein the injection amount is 5mg/kg based on the weight of the mice;
lipopolysaccharide was injected into the abdominal cavity 1h after the start of sepsis group test, the injection amount was 5mg/kg based on the weight of mice.
(3) Test method
After 25 hours from the start of the test, i.e., 24 hours after injection of physiological saline or lipopolysaccharide, the heart was removed, myocardial tissue was sectioned, mitochondria stained, and the sections were observed by electron microscopy.
The test results are shown in fig. 4, and it can be seen from the graph that compared with the control group, the mitochondria of the mice in the sepsis group are broken and cavitation appears, and the mitochondria of the test group after the galectin 1 is injected are obviously protected, so that the symptoms of myocardial tissue cell mitochondria destruction caused by sepsis can be effectively protected by the galectin 1 injection.
Example 4: mouse cardiomyocyte calcium transient and cell contraction assay
(1) Experimental animal
18 wild C57BL/6J mice are fed with standard maintenance feed in a constant temperature environment for at least 1 week before the experiment, and the drinking water is not limited.
(2) Grouping
Mice 18 were divided into 3 groups: control 6, test 6, sepsis 6.
Injecting physiological saline into the abdominal cavity 1h after the start of the test of the control group, wherein the injection amount is 5mg/kg based on the weight of the mice;
the test group test begins to inject the galectin 1 into the mice with the injection amount of 10 mug/mouse, and the lipopolysaccharide is injected into the abdominal cavity after 1h, wherein the injection amount is 5mg/kg based on the weight of the mice;
lipopolysaccharide was injected into the abdominal cavity 1h after the start of sepsis group test, the injection amount was 5mg/kg based on the weight of mice.
(3) Test method
After 25 hours from the start of the test, i.e., 24 hours after injection of physiological saline or lipopolysaccharide, the heart was removed, cardiomyocytes were isolated, and cardiomyocytes were directly observed by simultaneous cell contraction observation for cardiomyocyte contraction and calcium transient.
The test results show that compared with the control group, the myocardial cell contraction amplitude and the calcium homeostasis of mice in the sepsis group are obviously affected, and the myocardial cell contraction function and the calcium homeostasis of the test group after the galectin 1 is injected are effectively protected.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (3)
1. Use of galectin 1 in medicine for preventing and/or treating sepsis.
2. The use according to claim 1, wherein the medicament is a formulation prepared from an active ingredient comprising galectin 1 and a pharmaceutically acceptable galectin 1 derivative and an auxiliary ingredient comprising pharmaceutically acceptable excipients.
3. The use according to claim 1 or 2, wherein the dosage form of the medicament comprises an oral formulation or an injectable formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310757650.XA CN116570707A (en) | 2023-06-25 | 2023-06-25 | Application of galectin 1 in medicines for preventing and treating sepsis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310757650.XA CN116570707A (en) | 2023-06-25 | 2023-06-25 | Application of galectin 1 in medicines for preventing and treating sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116570707A true CN116570707A (en) | 2023-08-11 |
Family
ID=87534285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310757650.XA Pending CN116570707A (en) | 2023-06-25 | 2023-06-25 | Application of galectin 1 in medicines for preventing and treating sepsis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570707A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103314102A (en) * | 2010-12-09 | 2013-09-18 | 株式会社嘉尔药物 | Galectin 9-secreting cell, production method for same, and application for same |
-
2023
- 2023-06-25 CN CN202310757650.XA patent/CN116570707A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103314102A (en) * | 2010-12-09 | 2013-09-18 | 株式会社嘉尔药物 | Galectin 9-secreting cell, production method for same, and application for same |
Non-Patent Citations (1)
| Title |
|---|
| LÍLIAN C. RODRIGUES 等: "Galectin-1 modulation of neutrophil reactive oxygen species production depends on the cell activation state", 《MOLECULAR IMMUNOLOGY》, vol. 116, 31 December 2019 (2019-12-31), pages 80 - 89, XP085917707, DOI: 10.1016/j.molimm.2019.10.001 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways | |
| Zhang et al. | Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species | |
| WO2005082349A1 (en) | Composition for the treatment of obesity comprising fumagillol derivative | |
| Lv et al. | 6-Gingerol activates PI3K/Akt and inhibits apoptosis to attenuate myocardial ischemia/reperfusion injury | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| Yuan et al. | Preventive effects of total saponins of Panax japonicus on fatty liver fibrosis in mice | |
| Zhang et al. | Beneficial effects of andrographolide in a rat model of autoimmune myocarditis and its effects on PI3K/Akt pathway | |
| Han et al. | Liquiritin protects against cardiac fibrosis after myocardial infarction by inhibiting CCL5 expression and the NF-κB signaling pathway | |
| CN113440532B (en) | Application of brown algae oligosaccharide | |
| Tang et al. | Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. | |
| CN114191423B (en) | Application of small-molecule diterpene compound or salt thereof in preparation of medicine for preventing and treating acute lung injury | |
| Cheng et al. | Acid-sensing ion channel 3, but not capsaicin receptor TRPV1, plays a protective role in isoproterenol-induced myocardial ischemia in mice | |
| Zhang et al. | Hydroxysafflor yellow A attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting Erk5 signaling | |
| CN116570707A (en) | Application of galectin 1 in medicines for preventing and treating sepsis | |
| Zhu et al. | Ulinastatin reduces myocardial injury induced by doxorubicin in SD rats. | |
| Cai et al. | Xinshubao tablet ameliorates myocardial injury against heart failure via the DCN/PPARα/PGC-1α/P300 pathway | |
| CN112426434A (en) | Application of heparan sulfate in prevention and treatment of Alzheimer's disease | |
| CA3124178A1 (en) | Use of a par-1 antagonist for the treatment of a chronic inflammatory intestinal disease | |
| Chen et al. | Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats | |
| Wang et al. | Effects of propofol and etomidate pretreatment on glucocorticoid receptor expression following induction of sepsis in rats | |
| Tang et al. | Ameliorative effect of anisodamine (654-1/654-2) against myocardial dysfunction induced by septic shock via the NF-κB/NLRP-3 or the PI3K-AKT/NF-κB pathway | |
| CN117224558B (en) | Application of RNA editing enzyme inhibitor in preparation of medicines for preventing and/or treating hepatic fibrosis | |
| CN110604735B (en) | Compound for treating hepatic fibrosis and scleroderma and application thereof | |
| Kumar et al. | Advantage of Adrenomedullin as remedial contrivance for left ventricular remodeling after acute myocardial infarction | |
| Yin et al. | Protective effects of curcumin on hepatocytes in cecal ligation and puncture-induced sepsis in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |